|
Market Closed -
Toronto S.E.
18:34:25 26/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 16.61 CAD | -2.01% |
|
-1.07% | +30.48% |
| 10-18 | BioSyent Inc.(TSXV:RX) added to S&P/TSX Venture Composite Index | CI |
| 09-11 | BioSyent Inc., Q2 2026 Earnings Call, Aug 20, 2026 |
| Market Cap | 188M 134M 120M 111M 100M 12.75B 191M 1.33B 528M 6.67B 503M 492M 21.11B | P/E 2026 * |
16.6x | P/E 2027 * | 15.5x |
|---|---|---|---|---|---|
| Enterprise Value | 188M 134M 120M 111M 100M 12.75B 191M 1.33B 528M 6.67B 503M 492M 21.11B | EV / Sales 2026 * |
2.57x | EV / Sales 2027 * | 2.26x |
| Free-Float |
64.08% | Yield 2026 * |
-
| Yield 2027 * | - |
Toronto S.E.CAD
| Markets | Quality | ||
|---|---|---|---|
Toronto S.E.
| RX | Delayed | |
OTC Markets
| BIOYF | Delayed |
Last Transcript: BioSyent Inc.
| 1 day | -2.01% | ||
| 1 week | -1.07% | ||
| Current month | -0.54% | ||
| 1 month | +2.53% | ||
| 3 months | +12.69% | ||
| 6 months | +12.61% | ||
| Current year | +30.48% |
| 1 week | 16.25 |  | 17.07 |
| 1 month | 14.75 | | 17.15 |
| Current year | 12.25 | | 17.5 |
| 1 year | 10.65 | | 17.5 |
| 3 years | 7.75 | | 17.5 |
| 5 years | 6.24 | | 17.5 |
| 10 years | 3.13 | | 17.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 30/04/1999 |
Robert March
DFI | Director of Finance/CFO | - | 09/09/2018 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 31/05/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 31/05/1999 |
Peter Lockhard
BRD | Director/Board Member | 62 | 31/05/2002 |
Stephen Wilton
BRD | Director/Board Member | 65 | 15/01/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/10/26 | Option | Director | 747 | 0.0066% | ||
| 01/10/26 | Option | Director | 345 | 0.0031% | ||
| 01/10/26 | Option | Director | -691 | 0.0061% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.01% | -1.07% | +48.30% | +111.05% | 137M | |
| +0.45% | +3.13% | +54.96% | +125.16% | 1,135B | |
| +0.94% | +4.93% | +39.86% | +78.72% | 635B | |
| +0.39% | +1.44% | +25.77% | +97.48% | 505B | |
| +1.43% | +4.31% | +46.20% | +67.12% | 378B | |
| -3.21% | -2.10% | +60.72% | +33.22% | 358B | |
| -0.41% | +2.64% | +22.48% | +49.82% | 295B | |
| +0.23% | +3.66% | +2.57% | +23.69% | 266B | |
| +1.22% | +4.63% | +52.40% | +64.85% | 237B | |
| +1.70% | +3.67% | +31.21% | +102.15% | 193B | |
| Average | +0.04% | +2.51% | +38.45% | +75.33% | 400.38B | |
| Weighted average by Cap. | +0.42% | +2.85% | +41.40% | +83.61% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 73.2M 52.21M 46.69M 43.2M 39.11M 4.97B 74.4M 520M 206M 2.6B 196M 192M 8.23B | 83.2M 59.35M 53.07M 49.1M 44.45M 5.65B 84.56M 591M 234M 2.95B 223M 218M 9.35B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/10/26 | CA$16.61 | -2.01% | 40,057 |
| 22/10/26 | CA$16.95 | -0.70% | 11,018 |
| 21/10/26 | CA$17.07 | +0.65% | 350 |
| 20/10/26 | CA$16.96 | +1.01% | 4,479 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
16.61CAD
Average target price
18.00CAD
Spread / Average Target
+8.37%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
Select your edition
All financial news and data tailored to specific country editions
